MOACM
HRTX icon

Mutual of America Capital Management’s Heron Therapeutics HRTX Stock Holding History

Mutual of America Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-227,287
Closed -$234K – 1466
2023
Q3 		$234K Buy
227,287
+5,637
+3% +$8.02K ﹤0.01% 1332
2023
Q2 		$257K Buy
+221,650
New +$395K ﹤0.01% 1339

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Mutual of America Capital Management's HRTX Position: Q4 2023 in Review

Mutual of America Capital Management sold out of Heron Therapeutics (HRTX) in Q4 2023, closing a stake of 227,287 shares — an estimated $234K sold.

Mutual of America Capital Management first reported a position in HRTX in Q2 2023 and held it in 2 quarters. The position peaked at $257K in Q2 2023. 151 funds tracked by Wall St. Rank hold HRTX as of Q4 2023.

  • Mutual of America Capital Management reported no remaining Heron Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Mutual of America Capital Management sold 227,287 Heron Therapeutics shares in Q4 2023, an estimated $234K.
  • Mutual of America Capital Management first reported a position in Heron Therapeutics in Q2 2023 and held it in 2 quarters.
  • Mutual of America Capital Management's Heron Therapeutics position peaked at $257K in Q2 2023.
  • 151 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2023.

Based on Mutual of America Capital Management's 13F filing for Q4 2023, filed 26 Jan 2024.